Our
Product Pipeline


We take a scientifically driven approach to designing our ProTides, which have the potential to result in highly efficacious cancer therapies with improved tolerability.

Our pipeline of clinical product candidates is summarized below:

Applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.

Our
ProTide Candidates

Learn more about our leading ProTide candidates and our clinical studies


Acelarin (NUC-1031) Studies


Acelarin is being evaluated in several clinical studies, including a Phase III registrational study for patients with biliary tract cancer.

NUC-3373 Studies


NUC-3373 is being investigated in two clinical studies including a Phase Ib study in patients with advanced colorectal cancer.

NUC-7738 Studies


NUC-7738, is being investigated in a Phase I study for patients with advanced solid tumours.